Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study
Background Daclatasvir (DCV) is a potent, pangenotypic, hepatitis C virus (HCV) non-structural protein 5A inhibitor with low potential for drug interactions with antiretroviral therapy (ART). We evaluated the safety and efficacy of DCV plus peginterferon alfa-2a/ribavirin (PegIFN/RBV) in HIV-1/HCV g...
Saved in:
| Published in | Hepatology international Vol. 11; no. 2; pp. 188 - 198 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
New Delhi
Springer India
01.03.2017
Springer Nature B.V |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Background
Daclatasvir (DCV) is a potent, pangenotypic, hepatitis C virus (HCV) non-structural protein 5A inhibitor with low potential for drug interactions with antiretroviral therapy (ART). We evaluated the safety and efficacy of DCV plus peginterferon alfa-2a/ribavirin (PegIFN/RBV) in HIV-1/HCV genotype-1-coinfected patients.
Methods
AI444043 (NCT01471574), an open-label, Phase III, single-arm, response-guided treatment (RGT) study included 301 patients. They received DCV doses of 30, 60 or 90 mg once daily (depending on concomitant ART), plus weight-based RBV (<75 kg, 1000 mg/day; or ≥75 kg, 1200 mg/day), and once-weekly PegIFN 180 μg, for 24 weeks. If required by RGT, PegIFN/RBV without DCV was extended for an additional 24 weeks of therapy. The primary endpoint was the proportion of patients with sustained virologic response at post-treatment Week 12 (SVR12).
Results
Overall, 224 (74%) patients achieved SVR12 and the lower bound of the 95% confidence interval was higher than the historic SVR rate with PegIFN/RBV alone (70 vs. 29%). Most common adverse events (AEs) were fatigue, neutropenia, anemia, asthenia and headache. On-treatment serious AEs occurred in 24/301 (8%) patients; 18/301 (6%) discontinued treatment due to AE.
Conclusions
DCV + PegIFN/RBV led to sustained HCV virologic response in the majority of HIV-1-HCV-coinfected patients, regardless of concomitant ART. HIV control was not compromised and no new safety signals were identified. This study supports DCV use in HIV-1-HCV-coinfected patients, while allowing the vast majority of patients to remain on their existing ART regimen. |
|---|---|
| AbstractList | Daclatasvir (DCV) is a potent, pangenotypic, hepatitis C virus (HCV) non-structural protein 5A inhibitor with low potential for drug interactions with antiretroviral therapy (ART). We evaluated the safety and efficacy of DCV plus peginterferon alfa-2a/ribavirin (PegIFN/RBV) in HIV-1/HCV genotype-1-coinfected patients.
AI444043 (NCT01471574), an open-label, Phase III, single-arm, response-guided treatment (RGT) study included 301 patients. They received DCV doses of 30, 60 or 90 mg once daily (depending on concomitant ART), plus weight-based RBV (<75 kg, 1000 mg/day; or ≥75 kg, 1200 mg/day), and once-weekly PegIFN 180 μg, for 24 weeks. If required by RGT, PegIFN/RBV without DCV was extended for an additional 24 weeks of therapy. The primary endpoint was the proportion of patients with sustained virologic response at post-treatment Week 12 (SVR12).
Overall, 224 (74%) patients achieved SVR12 and the lower bound of the 95% confidence interval was higher than the historic SVR rate with PegIFN/RBV alone (70 vs. 29%). Most common adverse events (AEs) were fatigue, neutropenia, anemia, asthenia and headache. On-treatment serious AEs occurred in 24/301 (8%) patients; 18/301 (6%) discontinued treatment due to AE.
DCV + PegIFN/RBV led to sustained HCV virologic response in the majority of HIV-1-HCV-coinfected patients, regardless of concomitant ART. HIV control was not compromised and no new safety signals were identified. This study supports DCV use in HIV-1-HCV-coinfected patients, while allowing the vast majority of patients to remain on their existing ART regimen. Daclatasvir (DCV) is a potent, pangenotypic, hepatitis C virus (HCV) non-structural protein 5A inhibitor with low potential for drug interactions with antiretroviral therapy (ART). We evaluated the safety and efficacy of DCV plus peginterferon alfa-2a/ribavirin (PegIFN/RBV) in HIV-1/HCV genotype-1-coinfected patients.BACKGROUNDDaclatasvir (DCV) is a potent, pangenotypic, hepatitis C virus (HCV) non-structural protein 5A inhibitor with low potential for drug interactions with antiretroviral therapy (ART). We evaluated the safety and efficacy of DCV plus peginterferon alfa-2a/ribavirin (PegIFN/RBV) in HIV-1/HCV genotype-1-coinfected patients.AI444043 (NCT01471574), an open-label, Phase III, single-arm, response-guided treatment (RGT) study included 301 patients. They received DCV doses of 30, 60 or 90 mg once daily (depending on concomitant ART), plus weight-based RBV (<75 kg, 1000 mg/day; or ≥75 kg, 1200 mg/day), and once-weekly PegIFN 180 μg, for 24 weeks. If required by RGT, PegIFN/RBV without DCV was extended for an additional 24 weeks of therapy. The primary endpoint was the proportion of patients with sustained virologic response at post-treatment Week 12 (SVR12).METHODSAI444043 (NCT01471574), an open-label, Phase III, single-arm, response-guided treatment (RGT) study included 301 patients. They received DCV doses of 30, 60 or 90 mg once daily (depending on concomitant ART), plus weight-based RBV (<75 kg, 1000 mg/day; or ≥75 kg, 1200 mg/day), and once-weekly PegIFN 180 μg, for 24 weeks. If required by RGT, PegIFN/RBV without DCV was extended for an additional 24 weeks of therapy. The primary endpoint was the proportion of patients with sustained virologic response at post-treatment Week 12 (SVR12).Overall, 224 (74%) patients achieved SVR12 and the lower bound of the 95% confidence interval was higher than the historic SVR rate with PegIFN/RBV alone (70 vs. 29%). Most common adverse events (AEs) were fatigue, neutropenia, anemia, asthenia and headache. On-treatment serious AEs occurred in 24/301 (8%) patients; 18/301 (6%) discontinued treatment due to AE.RESULTSOverall, 224 (74%) patients achieved SVR12 and the lower bound of the 95% confidence interval was higher than the historic SVR rate with PegIFN/RBV alone (70 vs. 29%). Most common adverse events (AEs) were fatigue, neutropenia, anemia, asthenia and headache. On-treatment serious AEs occurred in 24/301 (8%) patients; 18/301 (6%) discontinued treatment due to AE.DCV + PegIFN/RBV led to sustained HCV virologic response in the majority of HIV-1-HCV-coinfected patients, regardless of concomitant ART. HIV control was not compromised and no new safety signals were identified. This study supports DCV use in HIV-1-HCV-coinfected patients, while allowing the vast majority of patients to remain on their existing ART regimen.CONCLUSIONSDCV + PegIFN/RBV led to sustained HCV virologic response in the majority of HIV-1-HCV-coinfected patients, regardless of concomitant ART. HIV control was not compromised and no new safety signals were identified. This study supports DCV use in HIV-1-HCV-coinfected patients, while allowing the vast majority of patients to remain on their existing ART regimen. Background Daclatasvir (DCV) is a potent, pangenotypic, hepatitis C virus (HCV) non-structural protein 5A inhibitor with low potential for drug interactions with antiretroviral therapy (ART). We evaluated the safety and efficacy of DCV plus peginterferon alfa-2a/ribavirin (PegIFN/RBV) in HIV-1/HCV genotype-1-coinfected patients. Methods AI444043 (NCT01471574), an open-label, Phase III, single-arm, response-guided treatment (RGT) study included 301 patients. They received DCV doses of 30, 60 or 90 mg once daily (depending on concomitant ART), plus weight-based RBV (<75 kg, 1000 mg/day; or ≥75 kg, 1200 mg/day), and once-weekly PegIFN 180 μg, for 24 weeks. If required by RGT, PegIFN/RBV without DCV was extended for an additional 24 weeks of therapy. The primary endpoint was the proportion of patients with sustained virologic response at post-treatment Week 12 (SVR12). Results Overall, 224 (74%) patients achieved SVR12 and the lower bound of the 95% confidence interval was higher than the historic SVR rate with PegIFN/RBV alone (70 vs. 29%). Most common adverse events (AEs) were fatigue, neutropenia, anemia, asthenia and headache. On-treatment serious AEs occurred in 24/301 (8%) patients; 18/301 (6%) discontinued treatment due to AE. Conclusions DCV + PegIFN/RBV led to sustained HCV virologic response in the majority of HIV-1-HCV-coinfected patients, regardless of concomitant ART. HIV control was not compromised and no new safety signals were identified. This study supports DCV use in HIV-1-HCV-coinfected patients, while allowing the vast majority of patients to remain on their existing ART regimen. Background Daclatasvir (DCV) is a potent, pangenotypic, hepatitis C virus (HCV) non-structural protein 5A inhibitor with low potential for drug interactions with antiretroviral therapy (ART). We evaluated the safety and efficacy of DCV plus peginterferon alfa-2a/ribavirin (PegIFN/RBV) in HIV-1/HCV genotype-1-coinfected patients. Methods AI444043 (NCT01471574), an open-label, Phase III, single-arm, response-guided treatment (RGT) study included 301 patients. They received DCV doses of 30, 60 or 90 mg once daily (depending on concomitant ART), plus weight-based RBV (<75 kg, 1000 mg/day; or [greater than or equal to]75 kg, 1200 mg/day), and once-weekly PegIFN 180 [mu]g, for 24 weeks. If required by RGT, PegIFN/RBV without DCV was extended for an additional 24 weeks of therapy. The primary endpoint was the proportion of patients with sustained virologic response at post-treatment Week 12 (SVR12). Results Overall, 224 (74%) patients achieved SVR12 and the lower bound of the 95% confidence interval was higher than the historic SVR rate with PegIFN/RBV alone (70 vs. 29%). Most common adverse events (AEs) were fatigue, neutropenia, anemia, asthenia and headache. On-treatment serious AEs occurred in 24/301 (8%) patients; 18/301 (6%) discontinued treatment due to AE. Conclusions DCV + PegIFN/RBV led to sustained HCV virologic response in the majority of HIV-1-HCV-coinfected patients, regardless of concomitant ART. HIV control was not compromised and no new safety signals were identified. This study supports DCV use in HIV-1-HCV-coinfected patients, while allowing the vast majority of patients to remain on their existing ART regimen. Daclatasvir (DCV) is a potent, pangenotypic, hepatitis C virus (HCV) non-structural protein 5A inhibitor with low potential for drug interactions with antiretroviral therapy (ART). We evaluated the safety and efficacy of DCV plus peginterferon alfa-2a/ribavirin (PegIFN/RBV) in HIV-1/HCV genotype-1-coinfected patients. AI444043 (NCT01471574), an open-label, Phase III, single-arm, response-guided treatment (RGT) study included 301 patients. They received DCV doses of 30, 60 or 90 mg once daily (depending on concomitant ART), plus weight-based RBV (<75 kg, 1000 mg/day; or greater than or equal to 75 kg, 1200 mg/day), and once-weekly PegIFN 180 mu g, for 24 weeks. If required by RGT, PegIFN/RBV without DCV was extended for an additional 24 weeks of therapy. The primary endpoint was the proportion of patients with sustained virologic response at post-treatment Week 12 (SVR12). Overall, 224 (74%) patients achieved SVR12 and the lower bound of the 95% confidence interval was higher than the historic SVR rate with PegIFN/RBV alone (70 vs. 29%). Most common adverse events (AEs) were fatigue, neutropenia, anemia, asthenia and headache. On-treatment serious AEs occurred in 24/301 (8%) patients; 18/301 (6%) discontinued treatment due to AE. DCV + PegIFN/RBV led to sustained HCV virologic response in the majority of HIV-1-HCV-coinfected patients, regardless of concomitant ART. HIV control was not compromised and no new safety signals were identified. This study supports DCV use in HIV-1-HCV-coinfected patients, while allowing the vast majority of patients to remain on their existing ART regimen. |
| Author | Rivero, Antonio Pineda, Juan Antonio Fessel, Walford J. Liu, Zhaohui McPhee, Fiona Lazzarin, Adriano Hughes, Eric Zakharova, Natalia Molina, Jean-Michel Mendez, Patricia Côté, Pierre Berenguer, Juan Hernandez, Dennis Ackerman, Peter Moreno, Christophe Pulido, Federico Rockstroh, Jurgen Eley, Timothy Noviello, Stephanie Sulkowski, Mark S. Cheinquer, Hugo Dieterich, Douglas Matthews, Gail Gadano, Adrian |
| Author_xml | – sequence: 1 givenname: Mark S. surname: Sulkowski fullname: Sulkowski, Mark S. email: msulkowski@jhmi.edu organization: Divisions of Infectious Diseases and Gastroenterology/Hepatology, Johns Hopkins Hospital, The Johns Hopkins University School of Medicine – sequence: 2 givenname: Walford J. surname: Fessel fullname: Fessel, Walford J. organization: Kaiser Permanente San Francisco Medical Center – sequence: 3 givenname: Adriano surname: Lazzarin fullname: Lazzarin, Adriano organization: Unit of Infectious Diseases, Clinica Malattie Infettive, Institute of Hospitalisation and Scientific Care – sequence: 4 givenname: Juan surname: Berenguer fullname: Berenguer, Juan organization: Unidad de Enfermedades Infecciosas/VIH , Instituto de Investigación Sanitaria Gregorio Marañón, Hospital General Universitario Gregorio Marañón – sequence: 5 givenname: Natalia surname: Zakharova fullname: Zakharova, Natalia organization: St Petersburg AIDS Center, SPT AIDS C 179A OBVODNIY CANAL – sequence: 6 givenname: Hugo surname: Cheinquer fullname: Cheinquer, Hugo organization: Servico De Gastroentereologia, Hospital De Clinicas De Porto Alegre – sequence: 7 givenname: Pierre surname: Côté fullname: Côté, Pierre organization: Clinique Medicale Du Quartier Latin – sequence: 8 givenname: Douglas surname: Dieterich fullname: Dieterich, Douglas organization: Institute for Liver Disease, Mount Sinai School of Medicine – sequence: 9 givenname: Adrian surname: Gadano fullname: Gadano, Adrian organization: Hospital Italiano De Buenos Aires – sequence: 10 givenname: Gail surname: Matthews fullname: Matthews, Gail organization: St Vincent’s Hospital (NSW) – sequence: 11 givenname: Jean-Michel surname: Molina fullname: Molina, Jean-Michel organization: Hopital Saint Louis – sequence: 12 givenname: Christophe surname: Moreno fullname: Moreno, Christophe organization: Hospital Erasme – sequence: 13 givenname: Juan Antonio surname: Pineda fullname: Pineda, Juan Antonio organization: Infectious Diseases and Microbiology Unit, Hospital Universitario de Valme – sequence: 14 givenname: Federico surname: Pulido fullname: Pulido, Federico organization: Hospital Universitario 12 De Octubre – sequence: 15 givenname: Antonio surname: Rivero fullname: Rivero, Antonio organization: Hospital Universitario Reina Sofia – sequence: 16 givenname: Jurgen surname: Rockstroh fullname: Rockstroh, Jurgen organization: Universitaetsklinikum Bonn, Medizinische Klinik – sequence: 17 givenname: Dennis surname: Hernandez fullname: Hernandez, Dennis organization: Department of Virology Discovery Biology, Bristol-Myers Squibb Research and Development – sequence: 18 givenname: Fiona surname: McPhee fullname: McPhee, Fiona organization: Department of Virology Discovery Biology, Bristol-Myers Squibb Research and Development – sequence: 19 givenname: Timothy surname: Eley fullname: Eley, Timothy organization: Bristol-Myers Squibb – sequence: 20 givenname: Zhaohui surname: Liu fullname: Liu, Zhaohui organization: Bristol-Myers Squibb, Hopewell – sequence: 21 givenname: Patricia surname: Mendez fullname: Mendez, Patricia organization: Bristol-Myers Squibb – sequence: 22 givenname: Eric surname: Hughes fullname: Hughes, Eric organization: Bristol-Myers Squibb – sequence: 23 givenname: Stephanie surname: Noviello fullname: Noviello, Stephanie organization: Bristol-Myers Squibb – sequence: 24 givenname: Peter surname: Ackerman fullname: Ackerman, Peter organization: Bristol-Myers Squibb |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28210927$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNks-KFDEQxhtZcf_oA3iRgBcPtibpnk7ibRlWZ2BBD7rXpjpdmc3Qk7RJeqX33Xw3MzvrIguKEEhR_L6qVOo7LY6cd1gULxl9xygV7yPjVPCSMlEqIWV5-6Q4YapqSrqo2dFDXFXHxWmMW0oXi4Y1z4pjLjmjiouT4ueFMVaDngm4nkQwmGbiDelBD5Ag3thAxmGKZMTNnDPYl9YlDAaDdwQGA4TDnTbYDjJtHclnDHhj_RSHmUwuBdwLyWp5ReLUbVGnSLS3zuQo53_YdE1W66u7Mntog86necSSfSBAvlxDRLJer98SP6IrB-hwIDFN_fy8eGpgiPji_j4rvn28-LpclZefP62X55elrukilQ2rOlUDZzUoVpteMI29rgxXKHoOEhE4MNH0rBKmMYZSih2tGy4aJbtOVGfFm0PdMfjvE8bU7mzUOAzgME_ZMimlyl9bV_-BNko1QtaLjL5-hG79FFweJFNCSVnRSmXq1T01dTvs2zHYHYS5_b3DDLADoIOPMaB5QBht9z5pDz5ps0_avU_a26wRjzTaJkjW52WBHf6p5AdlzF3cBsMfj_6r6BdAEtLj |
| CitedBy_id | crossref_primary_10_1093_jac_dkaa334 |
| Cites_doi | 10.1111/j.1365-2893.2009.01197.x 10.1056/NEJMoa1306218 10.1136/gutjnl-2014-307498 10.1001/archinte.166.15.1632 10.1053/j.gastro.2010.04.013 10.1056/NEJMoa1402454 10.1056/NEJMoa040842 10.1002/hep.23136 10.1002/hep.23020 10.1097/COH.0b013e32834bd365 10.1016/S2352-3018(15)00114-9 10.1056/NEJMoa1503153 10.1093/cid/cit103 10.1016/S1473-3099(15)70050-2 10.1097/QAD.0b013e32830e6d51 10.1038/nature08960 10.1001/jama.2012.7844 10.1128/AAC.02524-15 10.1001/jama.2015.1328 10.1056/NEJMoa1501315 10.1056/NEJMoa1316366 10.1056/NEJMoa1402355 10.1016/j.jhep.2015.04.009 10.1016/S0140-6736(03)14844-1 10.7326/0003-4819-147-10-200711200-00003 10.1016/S0140-6736(14)60604-8 10.1128/AAC.05977-11 10.1038/nature08309 10.3851/IMP2674 10.7326/M13-1829 10.1111/liv.13067 10.1016/j.jhep.2015.03.025 10.1055/s-0031-1295952 |
| ContentType | Journal Article |
| Copyright | Asian Pacific Association for the Study of the Liver 2017 Hepatology International is a copyright of Springer, 2017. |
| Copyright_xml | – notice: Asian Pacific Association for the Study of the Liver 2017 – notice: Hepatology International is a copyright of Springer, 2017. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7RV 7U7 7X7 7XB 88E 8AO 8FI 8FJ 8FK ABUWG AFKRA BENPR C1K CCPQU FYUFA GHDGH K9. KB0 M0S M1P NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 7U9 H94 |
| DOI | 10.1007/s12072-017-9788-z |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Toxicology Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central ProQuest Central UK/Ireland ProQuest Central Environmental Sciences and Pollution Management ProQuest One Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Health & Medical Collection Medical Database Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic Virology and AIDS Abstracts AIDS and Cancer Research Abstracts |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Toxicology Abstracts ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic AIDS and Cancer Research Abstracts Virology and AIDS Abstracts |
| DatabaseTitleList | MEDLINE MEDLINE - Academic ProQuest One Academic Middle East (New) AIDS and Cancer Research Abstracts |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1936-0541 |
| EndPage | 198 |
| ExternalDocumentID | 4321081343 28210927 10_1007_s12072_017_9788_z |
| Genre | Clinical Trial, Phase III Journal Article |
| GrantInformation_xml | – fundername: Bristol-Myers Squibb funderid: http://dx.doi.org/10.13039/100002491 |
| GroupedDBID | --- -5E -5G -BR -EM -Y2 -~C .86 .VR 06C 06D 0R~ 0VY 1N0 203 29I 29~ 2J2 2JN 2KG 2KM 2LR 2VQ 2~H 30V 3V. 4.4 406 408 40D 53G 5GY 5VS 67Z 6NX 7RV 7X7 88E 8AO 8FI 8FJ 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYTO AAYZH ABAKF ABDZT ABECU ABFTV ABHQN ABIPD ABJNI ABJOX ABKCH ABMNI ABMQK ABNWP ABPLI ABQBU ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABWNU ABXPI ACAOD ACCUX ACDTI ACGFS ACHSB ACHXU ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACSNA ACZOJ ADBBV ADHHG ADHIR ADINQ ADJJI ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFQL AEGAL AEGNC AEJHL AEJRE AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFKRA AFLOW AFQWF AFRAH AFWTZ AFZKB AGAYW AGDGC AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG AOIJS ARMRJ AXYYD B-. BAWUL BDATZ BENPR BGNMA BKEYQ BPHCQ BVXVI CAG CCPQU COF CS3 CSCUP DDRTE DIK DNIVK DPUIP DU5 E3Z EBLON EBS EIOEI EJD EN4 ESBYG EX3 F5P FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GX1 H13 HF~ HG6 HMCUK HMJXF HRMNR HYE HZ~ IJ- IKXTQ IMOTQ IWAJR IXD IZQ J-C J0Z JBSCW JZLTJ KOV LLZTM M1P M4Y MA- NAPCQ NPVJJ NQJWS NU0 O9- O93 O9I O9J OK1 P9S PF0 PQQKQ PROAC PSQYO PT4 QOR QOS R89 R9I ROL RPM RPX RSV S16 S1Z S27 S37 S3B SAP SDH SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SZ9 SZN T13 TR2 TSG TSK TT1 TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W48 WK8 WOW YLTOR Z45 Z7U Z87 ZMTXR ZOVNA ~A9 AAPKM AAYXX ABBRH ABDBE ABFSG ACSTC AEZWR AFDZB AFHIU AFOHR AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT CGR CUY CVF ECM EIF NPM 7U7 7XB 8FK ABRTQ C1K K9. PJZUB PKEHL PPXIY PQEST PQUKI PRINS 7X8 7U9 H94 |
| ID | FETCH-LOGICAL-c405t-613b94a214a914fd71cedc3f29e7d2a8eea2a176d137f6ff000eb04627698bb73 |
| IEDL.DBID | 7X7 |
| ISSN | 1936-0533 1936-0541 |
| IngestDate | Fri Jul 11 03:24:41 EDT 2025 Fri Jul 11 12:11:45 EDT 2025 Sat Jul 26 02:15:10 EDT 2025 Thu Apr 03 06:59:55 EDT 2025 Thu Jul 03 08:45:16 EDT 2025 Thu Apr 24 23:12:17 EDT 2025 Fri Feb 21 02:34:43 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | Daclatasvir HIV/HCV coinfection Peginterferon alfa-2a/ribavirin HCV GT-1 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c405t-613b94a214a914fd71cedc3f29e7d2a8eea2a176d137f6ff000eb04627698bb73 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| PMID | 28210927 |
| PQID | 1879883039 |
| PQPubID | 1486344 |
| PageCount | 11 |
| ParticipantIDs | proquest_miscellaneous_1888961643 proquest_miscellaneous_1869967845 proquest_journals_1879883039 pubmed_primary_28210927 crossref_primary_10_1007_s12072_017_9788_z crossref_citationtrail_10_1007_s12072_017_9788_z springer_journals_10_1007_s12072_017_9788_z |
| PublicationCentury | 2000 |
| PublicationDate | 20170300 2017-3-00 2017-03-00 20170301 |
| PublicationDateYYYYMMDD | 2017-03-01 |
| PublicationDate_xml | – month: 3 year: 2017 text: 20170300 |
| PublicationDecade | 2010 |
| PublicationPlace | New Delhi |
| PublicationPlace_xml | – name: New Delhi – name: United States – name: Tokyo |
| PublicationTitle | Hepatology international |
| PublicationTitleAbbrev | Hepatol Int |
| PublicationTitleAlternate | Hepatol Int |
| PublicationYear | 2017 |
| Publisher | Springer India Springer Nature B.V |
| Publisher_xml | – name: Springer India – name: Springer Nature B.V |
| References | CR19 Afdhal, Reddy, Nelson, Lawitz, Gordon, Schiff (CR27) 2014; 370 Lo, Kallan, Tate, Localio, Lim, Goetz (CR10) 2014; 160 CR39 CR16 CR15 CR37 CR14 CR32 Macias, Berenguer, Japon, Giron, Rivero, Lopez-Cortes (CR6) 2009; 50 Gao, Nettles, Belema, Snyder, Nguyen, Fridell (CR17) 2010; 465 Thompson, Muir, Sulkowski, Ge, Fellay, Shianna (CR40) 2010; 139 Kowdley, Gordon, Reddy, Rossaro, Bernstein, Lawitz (CR30) 2014; 370 Naggie, Cooper, Saag, Workowski, Ruane, Towner (CR31) 2015; 373 Andreoni, Giacometti, Maida, Meraviglia, Ripamonti, Sarmati (CR1) 2012; 16 Berenguer, Alvarez-Pellicer, Martin, Lopez-Aldeguer, Von Wichmann, Quereda (CR12) 2009; 50 Sulkowski, Gardiner, Rodriguez-Torres, Reddy, Hassanein, Jacobson (CR34) 2014; 370 Ge, Fellay, Thompson, Simon, Shianna, Urban (CR41) 2009; 461 Smith, Ryom, Weber, Morlat, Pradier, Reiss (CR2) 2014; 384 Thein, Yi, Dore, Krahn (CR7) 2008; 22 Afdhal, Zeuzem, Kwo, Chojkier, Gitlin, Puoti (CR26) 2014; 370 Bifano, Hwang, Oosterhuis, Hartstra, Grasela, Tiessen (CR36) 2013; 18 Limketkai, Mehta, Sutcliffe, Higgins, Torbenson, Brinkley (CR9) 2012; 308 Lalezari, Agarwal, Dusheiko, Brown, Brown, Weis, Christensen (CR23) 2011; 54 Bourlière, Bronowicki, de Ledinghen, Hézode, Zoulim, Mathurin (CR28) 2015; 15 Weber, Sabin, Friis-Moller, Reiss, El Sadr, Kirk (CR3) 2006; 166 Wyles, Ruane, Sulkowski, Dieterich, Luetkemeyer, Morgan (CR18) 2015; 373 Qurishi, Kreuzberg, Luchters, Effenberger, Kupfer, Sauerbruch (CR8) 2003; 362 CR24 Rockstroh, Nelson, Katlama, Lalezari, Mallolas, Bloch (CR33) 2015; 2 Torriani, Rodriguez-Torres, Rockstroh, Lissen, Gonzalez-Garcia, Lazzarin (CR20) 2004; 351 Hernandez, Sherman (CR4) 2011; 6 CR42 Mira, Rivero-Juarez, Lopez-Cortes, Giron-Gonzalez, Tellez, de Santos-Gil (CR13) 2013; 56 Cheng, Tian, Doehle, Peng, Corsa, Lee (CR22) 2016; 60 Hezode, Hirschfield, Ghesquiere, Sievert, Rodriguez-Torres, Shafran (CR21) 2015; 64 Reiberger, Ferlitsch, Sieghart, Kreil, Breitenecker, Rieger (CR5) 2010; 17 Veldt, Heathcote, Wedemeyer, Reichen, Hofmann, Zeuzem (CR11) 2007; 147 Wang, Huang, Valera, Sun, O’Boyle, Nower (CR25) 2012; 56 Forns, Gordon, Zuckerman, Lawitz, Calleja, Hofer (CR29) 2015; 63 Sulkowski, Eron, Wyles, Trinh, Lalezari, Wang (CR35) 2015; 313 Eley (CR38) 2015 MS Sulkowski (9788_CR35) 2015; 313 BJ Veldt (9788_CR11) 2007; 147 N Afdhal (9788_CR27) 2014; 370 JK Rockstroh (9788_CR33) 2015; 2 HH Thein (9788_CR7) 2008; 22 J Macias (9788_CR6) 2009; 50 C Wang (9788_CR25) 2012; 56 KV Kowdley (9788_CR30) 2014; 370 9788_CR42 CJ Smith (9788_CR2) 2014; 384 M Gao (9788_CR17) 2010; 465 G Cheng (9788_CR22) 2016; 60 T Reiberger (9788_CR5) 2010; 17 J Berenguer (9788_CR12) 2009; 50 9788_CR24 AJ Thompson (9788_CR40) 2010; 139 T Eley (9788_CR38) 2015 J Lalezari (9788_CR23) 2011; 54 X Forns (9788_CR29) 2015; 63 M Andreoni (9788_CR1) 2012; 16 R Weber (9788_CR3) 2006; 166 M Bourlière (9788_CR28) 2015; 15 MS Sulkowski (9788_CR34) 2014; 370 JA Mira (9788_CR13) 2013; 56 9788_CR32 BN Limketkai (9788_CR9) 2012; 308 9788_CR15 9788_CR37 9788_CR16 DL Wyles (9788_CR18) 2015; 373 FJ Torriani (9788_CR20) 2004; 351 D Ge (9788_CR41) 2009; 461 9788_CR39 N Afdhal (9788_CR26) 2014; 370 RV Lo III (9788_CR10) 2014; 160 S Naggie (9788_CR31) 2015; 373 9788_CR14 MD Hernandez (9788_CR4) 2011; 6 9788_CR19 M Bifano (9788_CR36) 2013; 18 N Qurishi (9788_CR8) 2003; 362 C Hezode (9788_CR21) 2015; 64 |
| References_xml | – volume: 17 start-page: 400 year: 2010 end-page: 409 ident: CR5 article-title: HIV–HCV co-infected patients with low CD4 + cell nadirs are at risk for faster fibrosis progression and portal hypertension publication-title: J Viral Hepat doi: 10.1111/j.1365-2893.2009.01197.x – volume: 370 start-page: 211 year: 2014 end-page: 221 ident: CR34 article-title: Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection publication-title: N Engl J Med doi: 10.1056/NEJMoa1306218 – volume: 64 start-page: 948 year: 2015 end-page: 956 ident: CR21 article-title: Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study publication-title: Gut doi: 10.1136/gutjnl-2014-307498 – volume: 166 start-page: 1632 year: 2006 end-page: 1641 ident: CR3 article-title: Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study publication-title: Arch Intern Med doi: 10.1001/archinte.166.15.1632 – volume: 139 start-page: 120 year: 2010 end-page: 129 ident: CR40 article-title: Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus publication-title: Gastroenterology doi: 10.1053/j.gastro.2010.04.013 – volume: 16 start-page: 1473 year: 2012 end-page: 1483 ident: CR1 article-title: HIV–HCV co-infection: epidemiology, pathogenesis and therapeutic implications publication-title: Eur Rev Med Pharmacol Sci – ident: CR14 – volume: 370 start-page: 1889 year: 2014 end-page: 1898 ident: CR26 article-title: Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection publication-title: N Engl J Med doi: 10.1056/NEJMoa1402454 – ident: CR39 – ident: CR16 – ident: CR37 – volume: 351 start-page: 438 year: 2004 end-page: 450 ident: CR20 article-title: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients publication-title: N Engl J Med doi: 10.1056/NEJMoa040842 – year: 2015 ident: CR38 publication-title: Company updates on clinical pharmacology and DDI profile of HCV drugs recently launched and in the pipeline: focus on DDIs between daclatasvir and HIV medicines – volume: 50 start-page: 1056 year: 2009 end-page: 1063 ident: CR6 article-title: Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus publication-title: Hepatology doi: 10.1002/hep.23136 – volume: 50 start-page: 407 year: 2009 end-page: 413 ident: CR12 article-title: Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus publication-title: Hepatology doi: 10.1002/hep.23020 – volume: 6 start-page: 478 year: 2011 end-page: 482 ident: CR4 article-title: HIV/hepatitis C coinfection natural history and disease progression publication-title: Curr Opin HIV AIDS doi: 10.1097/COH.0b013e32834bd365 – volume: 2 start-page: e319 year: 2015 end-page: e327 ident: CR33 article-title: Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial publication-title: Lancet HIV doi: 10.1016/S2352-3018(15)00114-9 – volume: 373 start-page: 714 year: 2015 end-page: 725 ident: CR18 article-title: Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1 publication-title: N Engl J Med doi: 10.1056/NEJMoa1503153 – volume: 56 start-page: 1646 year: 2013 end-page: 1653 ident: CR13 article-title: Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis publication-title: Clin Infect Dis doi: 10.1093/cid/cit103 – volume: 15 start-page: 397 year: 2015 end-page: 404 ident: CR28 article-title: Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS) publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(15)70050-2 – volume: 22 start-page: 1979 year: 2008 end-page: 1991 ident: CR7 article-title: Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis publication-title: AIDS doi: 10.1097/QAD.0b013e32830e6d51 – volume: 465 start-page: 96 year: 2010 end-page: 100 ident: CR17 article-title: Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect publication-title: Nature doi: 10.1038/nature08960 – volume: 308 start-page: 370 year: 2012 end-page: 378 ident: CR9 article-title: Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV publication-title: JAMA doi: 10.1001/jama.2012.7844 – volume: 60 start-page: 1847 year: 2016 end-page: 1853 ident: CR22 article-title: In vitro antiviral activity and resistance profile characterization of the hepatitis C virus NS5A inhibitor ledipasvir publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.02524-15 – volume: 313 start-page: 1223 year: 2015 end-page: 1231 ident: CR35 article-title: Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial publication-title: JAMA doi: 10.1001/jama.2015.1328 – ident: CR42 – volume: 373 start-page: 705 year: 2015 end-page: 713 ident: CR31 article-title: Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1 publication-title: N Engl J Med doi: 10.1056/NEJMoa1501315 – ident: CR19 – volume: 370 start-page: 1483 year: 2014 end-page: 1493 ident: CR27 article-title: Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection publication-title: N Engl J Med doi: 10.1056/NEJMoa1316366 – volume: 370 start-page: 1879 year: 2014 end-page: 1888 ident: CR30 article-title: Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis publication-title: N Engl J Med doi: 10.1056/NEJMoa1402355 – ident: CR15 – volume: 63 start-page: 564 year: 2015 end-page: 572 ident: CR29 article-title: Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent publication-title: J Hepatol doi: 10.1016/j.jhep.2015.04.009 – volume: 362 start-page: 1708 year: 2003 end-page: 1713 ident: CR8 article-title: Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection publication-title: Lancet doi: 10.1016/S0140-6736(03)14844-1 – volume: 147 start-page: 677 year: 2007 end-page: 684 ident: CR11 article-title: Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis publication-title: Ann Intern Med doi: 10.7326/0003-4819-147-10-200711200-00003 – volume: 160 start-page: 369 year: 2014 end-page: 379 ident: CR10 article-title: Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study publication-title: Ann Intern Med – ident: CR32 – volume: 384 start-page: 241 year: 2014 end-page: 248 ident: CR2 article-title: Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration publication-title: Lancet doi: 10.1016/S0140-6736(14)60604-8 – volume: 56 start-page: 1350 year: 2012 end-page: 1358 ident: CR25 article-title: Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052 publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.05977-11 – volume: 54 start-page: 360A issue: (Suppl 1) year: 2011 end-page: 1445A ident: CR23 article-title: Dose-ranging trial of PPI-461, a potent new pan-genotypic HCV NS5A inhibitor, in patients with HCV genotype-1 infection publication-title: Hepatol – volume: 461 start-page: 399 year: 2009 end-page: 401 ident: CR41 article-title: Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance publication-title: Nature doi: 10.1038/nature08309 – ident: CR24 – volume: 18 start-page: 931 year: 2013 end-page: 940 ident: CR36 article-title: Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir publication-title: Antivir Ther doi: 10.3851/IMP2674 – volume: 351 start-page: 438 year: 2004 ident: 9788_CR20 publication-title: N Engl J Med doi: 10.1056/NEJMoa040842 – volume: 313 start-page: 1223 year: 2015 ident: 9788_CR35 publication-title: JAMA doi: 10.1001/jama.2015.1328 – volume: 373 start-page: 705 year: 2015 ident: 9788_CR31 publication-title: N Engl J Med doi: 10.1056/NEJMoa1501315 – volume: 139 start-page: 120 year: 2010 ident: 9788_CR40 publication-title: Gastroenterology doi: 10.1053/j.gastro.2010.04.013 – ident: 9788_CR37 – ident: 9788_CR14 – volume: 166 start-page: 1632 year: 2006 ident: 9788_CR3 publication-title: Arch Intern Med doi: 10.1001/archinte.166.15.1632 – ident: 9788_CR16 – volume: 160 start-page: 369 year: 2014 ident: 9788_CR10 publication-title: Ann Intern Med doi: 10.7326/M13-1829 – ident: 9788_CR32 doi: 10.1111/liv.13067 – volume: 6 start-page: 478 year: 2011 ident: 9788_CR4 publication-title: Curr Opin HIV AIDS doi: 10.1097/COH.0b013e32834bd365 – volume: 308 start-page: 370 year: 2012 ident: 9788_CR9 publication-title: JAMA doi: 10.1001/jama.2012.7844 – volume: 15 start-page: 397 year: 2015 ident: 9788_CR28 publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(15)70050-2 – volume: 16 start-page: 1473 year: 2012 ident: 9788_CR1 publication-title: Eur Rev Med Pharmacol Sci – ident: 9788_CR19 – volume: 56 start-page: 1646 year: 2013 ident: 9788_CR13 publication-title: Clin Infect Dis doi: 10.1093/cid/cit103 – volume: 50 start-page: 1056 year: 2009 ident: 9788_CR6 publication-title: Hepatology doi: 10.1002/hep.23136 – ident: 9788_CR15 doi: 10.1016/j.jhep.2015.03.025 – volume: 373 start-page: 714 year: 2015 ident: 9788_CR18 publication-title: N Engl J Med doi: 10.1056/NEJMoa1503153 – volume: 56 start-page: 1350 year: 2012 ident: 9788_CR25 publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.05977-11 – volume: 60 start-page: 1847 year: 2016 ident: 9788_CR22 publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.02524-15 – volume: 384 start-page: 241 year: 2014 ident: 9788_CR2 publication-title: Lancet doi: 10.1016/S0140-6736(14)60604-8 – volume: 465 start-page: 96 year: 2010 ident: 9788_CR17 publication-title: Nature doi: 10.1038/nature08960 – ident: 9788_CR24 doi: 10.1055/s-0031-1295952 – volume: 63 start-page: 564 year: 2015 ident: 9788_CR29 publication-title: J Hepatol doi: 10.1016/j.jhep.2015.04.009 – volume: 147 start-page: 677 year: 2007 ident: 9788_CR11 publication-title: Ann Intern Med doi: 10.7326/0003-4819-147-10-200711200-00003 – volume-title: Company updates on clinical pharmacology and DDI profile of HCV drugs recently launched and in the pipeline: focus on DDIs between daclatasvir and HIV medicines year: 2015 ident: 9788_CR38 – volume: 22 start-page: 1979 year: 2008 ident: 9788_CR7 publication-title: AIDS doi: 10.1097/QAD.0b013e32830e6d51 – volume: 370 start-page: 1483 year: 2014 ident: 9788_CR27 publication-title: N Engl J Med doi: 10.1056/NEJMoa1316366 – volume: 50 start-page: 407 year: 2009 ident: 9788_CR12 publication-title: Hepatology doi: 10.1002/hep.23020 – volume: 18 start-page: 931 year: 2013 ident: 9788_CR36 publication-title: Antivir Ther doi: 10.3851/IMP2674 – volume: 370 start-page: 211 year: 2014 ident: 9788_CR34 publication-title: N Engl J Med doi: 10.1056/NEJMoa1306218 – volume: 17 start-page: 400 year: 2010 ident: 9788_CR5 publication-title: J Viral Hepat doi: 10.1111/j.1365-2893.2009.01197.x – volume: 54 start-page: 360A issue: (Suppl 1) year: 2011 ident: 9788_CR23 publication-title: Hepatol – ident: 9788_CR42 – volume: 362 start-page: 1708 year: 2003 ident: 9788_CR8 publication-title: Lancet doi: 10.1016/S0140-6736(03)14844-1 – volume: 370 start-page: 1889 year: 2014 ident: 9788_CR26 publication-title: N Engl J Med doi: 10.1056/NEJMoa1402454 – ident: 9788_CR39 – volume: 2 start-page: e319 year: 2015 ident: 9788_CR33 publication-title: Lancet HIV doi: 10.1016/S2352-3018(15)00114-9 – volume: 461 start-page: 399 year: 2009 ident: 9788_CR41 publication-title: Nature doi: 10.1038/nature08309 – volume: 64 start-page: 948 year: 2015 ident: 9788_CR21 publication-title: Gut doi: 10.1136/gutjnl-2014-307498 – volume: 370 start-page: 1879 year: 2014 ident: 9788_CR30 publication-title: N Engl J Med doi: 10.1056/NEJMoa1402355 |
| SSID | ssj0055616 |
| Score | 2.081356 |
| Snippet | Background
Daclatasvir (DCV) is a potent, pangenotypic, hepatitis C virus (HCV) non-structural protein 5A inhibitor with low potential for drug interactions... Daclatasvir (DCV) is a potent, pangenotypic, hepatitis C virus (HCV) non-structural protein 5A inhibitor with low potential for drug interactions with... Background Daclatasvir (DCV) is a potent, pangenotypic, hepatitis C virus (HCV) non-structural protein 5A inhibitor with low potential for drug interactions... |
| SourceID | proquest pubmed crossref springer |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 188 |
| SubjectTerms | Adult Aged Antiviral Agents - administration & dosage Antiviral Agents - adverse effects Antiviral Agents - therapeutic use Coinfection - drug therapy Coinfection - virology Colorectal Surgery Drug Therapy, Combination Female Hepacivirus - drug effects Hepacivirus - genetics Hepatitis C virus Hepatitis C, Chronic - complications Hepatitis C, Chronic - drug therapy Hepatology HIV Infections - complications HIV Infections - drug therapy Humans Imidazoles - administration & dosage Imidazoles - adverse effects Imidazoles - therapeutic use Interferon-alpha - administration & dosage Interferon-alpha - adverse effects Interferon-alpha - therapeutic use Lentivirus Male Medicine Medicine & Public Health Middle Aged Original Article Polyethylene Glycols - administration & dosage Polyethylene Glycols - adverse effects Polyethylene Glycols - therapeutic use Recombinant Proteins - administration & dosage Recombinant Proteins - adverse effects Recombinant Proteins - therapeutic use Retroviridae Ribavirin - administration & dosage Ribavirin - therapeutic use Surgery Treatment Outcome Young Adult |
| SummonAdditionalLinks | – databaseName: SpringerLink Journals (ICM) dbid: U2A link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlR3LitRAsNEVxIv4NrpKCZ7UwCTpSXe8LcsuM8KKB2fZW6h-6UBIhsmMMPtv_ptVecwqqwtCTp3qpumqrkfXS4i30uFkanwRq7wwsZSG-CAJhjgEY5IJ5rrPkDv7nM8W8tPF9GLI427HaPfRJdlx6qtkt3SiOIxAxWT56PjytrgzZdOdiHiRHo3sl9s95r0rmUxlUmZGV-bflvhTGF3TMK95Rzuhc_pA3B-0RTjq0ftQ3PL1I3H3bPCHPxY_T7gCBNodYO2gxeA3O2gCOLQVbrD9sVzDqtq2sPLfdjTiXcz1IdbBr5sasAoIKXZz10uDBL2sgb4Vx_4227bawbbuQtG9g9nxObRbw-82Ldimj-KicX7Jhdn8vFuGgbjsK7_sxslHQPjyneQkzOfzD8CdumKiOl9BV9X2iVicnnw9nsVDQ4bYkl63ITMzM4XENJFYJDI4lVjvbBbSwiuXovYeU0xU7pJMhTwEYrfecPYrEYI2RmVPxUHd1P65AM1DigAzaaRGYzIbMExTq3ThrEsiMRkxU9qhWjk3zajKqzrLjMySkFkyMsvLSLzbT1n1pTpuAj4c0V0Ot7YtufO61iTUi0i82f-m-8ZOFKw9HXzJLbwKkvByehOM1gWRocwi8awnpf2OyMRNJkWqIvF-pK3fNvCv7b74L-iX4l7KRN6Fyh2Kg81661-R7rQxr7u78gtkWxIo priority: 102 providerName: Springer Nature |
| Title | Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study |
| URI | https://link.springer.com/article/10.1007/s12072-017-9788-z https://www.ncbi.nlm.nih.gov/pubmed/28210927 https://www.proquest.com/docview/1879883039 https://www.proquest.com/docview/1869967845 https://www.proquest.com/docview/1888961643 |
| Volume | 11 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR1ri9NAcNE7EL-I76uexwp-UhebZJvd-EXq0btWueMQe9RPYZ9aCElMWqH33_xvzuTRUw4LIYHNbFgys_PeGUJecauGI-0SJuJEM8418EEQDMx7rYOhimV7Qu7sPJ7O-afFaNE53OourbLniQ2jtoVBH_k77IotJTDc5EP5k2HXKIyudi00bpN9LF2GKV1isTW4sPNj3EaVwWoGvaaPajZH58KhwKQEwcCOkuzqX7l0Q9m8ESht5M_JfXKvUxzpuMX0A3LL5Q_JnbMuNP6I_J5gMQhlNlTlltbKu9WGFp5aZTK1UvWvZUXLbF3T0n3fwIizDEtFVN5VRU5V5hUNVTO3WmoF0MucwlViGnCxrrMNXedNVrqzdHp8Seu1RhdOTU3RJnTBODp16XR22XwGgbACLDp5WfCeKnrxA0Qmnc1mbyk27WJAgC6jTYHbx2R-Mvl6PGVdbwZmQMVbgcUZ6YSrMOAqCbi3IjDOmsiHiRM2VNI5FapAxDaIhI-9B87rNB6EBZqQWovoCdnLi9wdECpxSABgxDWXSuvIeOVHoREyscYGAzLsMZOarnA59s_I0uuSy4jMFJCZIjLTqwF5vZ1StlU7dgEf9uhOuw1cp9fkNiAvt69h62E8ReUOfnyK3bwSEPZ8tAtGygTIkEcD8rQlpe2KwNoNhkkoBuRNT1t_LeB_y322e7nPyd0QqbpJkzske6tq7V6A3rTSR83mOCL749Nvnyfw_Dg5v_gCo6eLAO7zcPwHWAAaJQ |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR1db9Mw0BqdBHtBfK8wwEjwAkQ0jhs7SAjB6NSwtZrQNu0ts2MbKkVJaVpQ96P4B_w37vLRgSb6NilPztm65M734TvfEfKcG9Xraxt5Ioy0x7kGOQiKwXNOa7-nQlnfkBuNw-Ex_3zaP90gv9q7MJhW2crESlCbIsUz8jfYFVtKELjR--l3D7tGYXS1baFRs8W-Xf4El618F38C-r5gbG9wtDv0mq4CXgrGyRx8pUBHXDGfq8jnzgg_tSYNHIusMExJaxVTvgiNHwgXOgcyw2q8wglfI7UWAax7jWzyAFyZDtn8OBgffmllP_aaDOs4NvjpYEm1cdTqsh7rCUyDEB54btI7_1cTXjJvL4VmK423d4vcbExV-qHmrdtkw-Z3yPVRE4y_S34PsPyESpdU5YaWytn5khaOGpVmaq7KH5MZnWaLkk7t1yWMWONhcYqZs7MipypzijJVzZ1NtALoSU7hmWLicbEosyVd5FUevDV0uHtCy4XGQ6OSpkWdQgbjeIxMh_FJtQwCYc1ZPFb2_LdU0cNvoKRpHMevKbYJ84DlbUarkrr3yPGV0O0-6eRFbrcJlTgkADDgmkuldZA65fosFTIyqfG7pNdSJkmbUunYsSNLLoo8IzETIGaCxEzOu-Tlasq0rhOyDninJXfSiIwyuWDwLnm2eg2bHSM4Krfw4xPsHxaBecH762CkjIANedAlD2pWWmEE_rXfi5joklctb_2FwP_Qfbge3afkxvBodJAcxOP9R2SLIYdXSXo7pDOfLexjsNrm-kmzVSg5u-rd-Qc3vFNw |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELdgSBMviG8KAw6JJyBak7ixw9s0VrXApj3QaW_RObZHpSitmhSp-9_437jLRwcaTELKk3OOrNz57uy7-50Qb6XF4ci4NFBJagIpDelBMgyB98aEQ0x0WyF3fJJMZvLz-ei863Na9dnufUiyrWlglKay3l9av39V-BYNFacUqIBOQTq4vC3ukDYOWaxn0UGvirn1Y9KGlenYTI5NH9b82yf-NEzXvM1rkdLGAI3vi3ud5wgHLasfiFuufCh2j7vY-CPx84jRIDDfAJYWKvSu3sDCg8W8wBqrH_MVLIt1BUt3saERZwPGilh5t1qUgIVHiLCZu5obJOp5CfQsOQ94sa6KDazLJi3dWZgcnkG1NnyHU0G-aDO6aJxvdWEyPWs-w0QMAcu3vEH4ERBOv5PNhOl0-gG4a1dAEugKaBBuH4vZ-Ojb4STomjMEOfl4NR05Y5NKjEKJaSi9VWHubB77KHXKRqidwwhDldgwVj7xnlSvM1wJS0KhjVHxE7FTLkr3TIDmIUWEsTRSozFx7tGPolzp1OY2HIhhz5ks75DLuYFGkV1hLjMzM2JmxszMLgfi3XbKsoXtuIl4r2d31u3gKuMu7FqTgU8H4s32Ne09Dqhg6ejHZ9zOKyVrL0c30WidkhjKeCCetqK0XREdd8NhGqmBeN_L1m8L-Ndyn_8X9Wuxe_ppnH2dnnx5Ie5GLO9NBt2e2KlXa_eSXKravGq2zS8IKRlX |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Efficacy+and+safety+of+daclatasvir+plus+pegylated-interferon+alfa+2a+and+ribavirin+in+previously+untreated+HCV+subjects+coinfected+with+HIV+and+HCV+genotype-1%3A+a+Phase+III%2C+open-label+study&rft.jtitle=Hepatology+international&rft.au=Sulkowski%2C+Mark+S&rft.au=Fessel%2C+Walford+J&rft.au=Lazzarin%2C+Adriano&rft.au=Berenguer%2C+Juan&rft.date=2017-03-01&rft.pub=Springer+Nature+B.V&rft.issn=1936-0533&rft.eissn=1936-0541&rft.volume=11&rft.issue=2&rft.spage=188&rft_id=info:doi/10.1007%2Fs12072-017-9788-z&rft.externalDocID=4321081343 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1936-0533&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1936-0533&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1936-0533&client=summon |